NDA 217469 · Harrow Eye
Vevye
Cyclosporine · Ophthalmic · Calcineurin Inhibitor Immunosuppressant
Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 30, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,166
250 Phase 3, 65 recruiting
FAERS reports
6,159
85 serious, 5 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 26, 2026.
VEVYE indicated for the treatment of the signs and symptoms of dry eye disease. VEVYE (cyclosporine ophthalmic solution) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )
Mechanism: Cyclosporine, a calcineurin inhibitor, is a relatively selective immunomodulatory drug.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VEVYE · CYCLOSPORINE 0.1% · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.
University Hospital, AngersGovernment (non-federal)
NCT02416388 · 3,100 participants (planned) · Start Jan 2015 · Primary completion Jul 30, 2025
Drug: Idarubicin; Daunorubicin and 8 more · For: Acute Myeloid Leukemia (AML)
Sites: Amiens, France; Angers, France; Argenteuil, France · 56 sites in all
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesPivotal-lookingTerminated
Atrial Fibrillation NetworkAcademic, hospital or other
NCT02618577 · 2,608 participants · Start Feb 2016 · Primary completion Dec 31, 2022
Drug: Edoxaban; ASA · For: Atrial High Rate Episodes
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Bulgaria · 18 sites in all
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01950819 · 2,037 participants · Start Dec 3, 2013 · Primary completion Feb 1, 2017
Drug: Induction therapy; Corticosteroids and 2 more · For: End Stage Renal Disease (ESRD); Chronic Kidney Disease (CKD); Hemodialysis and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Los Angeles, California · 184 sites in all
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
Merck KGaA, Darmstadt, GermanyIndustry
NCT00249808 · 1,266 participants · Start Dec 13, 2004 · Primary completion Jan 25, 2007
Drug: Efalizumab - anti-CD11a recombinant human monoclonal antibody · For: Psoriasis
Sites: Feltham, United Kingdom
- Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60aPivotal-lookingCompleted
University of LeipzigAcademic, hospital or other
NCT01497002 · 1,222 participants · Start Apr 2005 · Primary completion Jul 18, 2018
Drug: Cytarabine; human stem cells · For: Acute Myeloid Leukaemia
Sites: Leipzig, Germany
- Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to FluorouracilPivotal-lookingCompleted
University of LeedsAcademic, hospital or other
NCT00389870 · 1,198 participants · Start Dec 2006
Drug: panitumumab; cyclosporine and 1 more · For: Colorectal Cancer
Sites: Bournemouth, United Kingdom; Brighton, United Kingdom; Bristol, United Kingdom · 33 sites in all
- Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) PatientsPivotal-lookingCompleted
Hospices Civils de LyonAcademic, hospital or other
NCT01502774 · 970 participants · Start Apr 2011 · Primary completion Feb 2015
Drug: Injection of Cyclosporin; Placebo · For: ST Elevation Acute Myocardial Infarction
Sites: Bruges, Belgium; Charleroi, Belgium; Edegem, Belgium · 45 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation2,454
- drug ineffective1,688
- eye pain916
- ocular hyperaemia538
- vision blurred479
- eye pruritus407
- dry eye296
- lacrimation increased272
- ocular discomfort243
- headache209
- drug hypersensitivity205
- eye swelling159
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 974 |
| 2025 | 1,814 |
| 2026 | 3,368 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vevye (Cyclosporine)
2024 spending
$13.2M
Beneficiaries
5,877
15,393 claims
Per beneficiary
$2,249
$366.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $13,217,841 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, et al. · N Engl J Med 2019 · Equivalence Trial, Multicenter Study
- A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, et al. · Am J Transplant 2010 · Clinical Trial, Phase III, Multicenter Study
- Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysis.
Vuyyuru SK, Shaban N, Yuan Y, et al. · Clin Gastroenterol Hepatol 2025 · Systematic Review, Meta-Analysis
- Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial.
Kadatz M, Klarenbach S, So H, et al. · Nephrol Dial Transplant 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Harrow Eye
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.